B. Riley Expects Stronger Earnings for PDS Biotechnology

PDS Biotechnology Co. (NASDAQ:PDSB) – Investment analysts at B. Riley lifted their Q1 2025 earnings estimates for PDS Biotechnology in a report released on Monday, April 21st. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.34). The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. B. Riley also issued estimates for PDS Biotechnology’s Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at $0.10 EPS.

Separately, HC Wainwright reduced their price target on shares of PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

PDS Biotechnology Stock Up 7.3 %

Shares of PDS Biotechnology stock opened at $1.32 on Thursday. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a 1 year low of $0.85 and a 1 year high of $4.42. The stock has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.84. The company has a market cap of $59.92 million, a P/E ratio of -1.14 and a beta of 1.50.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, March 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08.

Institutional Investors Weigh In On PDS Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in PDSB. Geode Capital Management LLC raised its position in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock valued at $1,586,000 after acquiring an additional 37,142 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology during the 4th quarter valued at $26,000. Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology in the 4th quarter valued at $89,000. Blair William & Co. IL boosted its holdings in PDS Biotechnology by 29.4% in the fourth quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock worth $257,000 after purchasing an additional 35,757 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in PDS Biotechnology by 331.0% during the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after buying an additional 76,800 shares during the last quarter. 26.84% of the stock is owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.